cyc 202 has been researched along with docetaxel anhydrous in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | cyc 202 (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Compton, DA; DiRenzo, J; Dmitrovsky, E; Galimberti, F; Green, SR; Greninger, P; Li, H; Liu, X; Memoli, V; Settleman, J; Sharma, SV; Thompson, SL | 1 |
2 other study(ies) available for cyc 202 and docetaxel anhydrous
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
Topics: Anaphase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Docetaxel; Drug Delivery Systems; Lung Neoplasms; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Purines; Roscovitine; Taxoids | 2010 |